Treatment of menstrual migraine: Utility of control of related mood disturbances

Andrea Negro, Flavia Napoletano, Luana Lionetto, Francesco Marsibilio, Gabriele Sani, Paolo Girardi, Paolo Martelletti

Research output: Contribution to journalArticlepeer-review


Menstrual migraine (MM) has a prevalence in the general population of approximately 7%, although it seems to be much higher within the population of females with migraine. Episodes of MM have been reported to be longer, more intense, more disabling, less responsive to acute therapy and more prone to recurrence than those of other types of migraine. MM is demonstrated to have a bi-directional link to affective illnesses such as premenstrual dysphoric disorder and depression. There is clinical and pathophysiological evidence suggesting that the relationship between MM and affective disorders could be linked to ovarian hormones. The aim of this review is to analyze treatment strategies in patients with co-existent MM and affective disorders.

Original languageEnglish
Pages (from-to)493-502
Number of pages10
JournalExpert Review of Neurotherapeutics
Issue number5
Publication statusPublished - 2014


  • affective disorders
  • comorbidity
  • estrogens
  • menstrual migraine
  • non-steroidal anti-inflammatory drugs
  • premenstrual syndrome
  • triptans

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology (medical)
  • Medicine(all)


Dive into the research topics of 'Treatment of menstrual migraine: Utility of control of related mood disturbances'. Together they form a unique fingerprint.

Cite this